Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Oct;78(7):945–949. doi: 10.1038/bjc.1998.606

Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.

D F Hargreaves 1, F Knox 1, R Swindell 1, C S Potten 1, N J Bundred 1
PMCID: PMC2063113  PMID: 9764588

Abstract

The proliferation rate (as assessed by Ki67 expression) and expression of oestrogen-regulated progesterone receptor (PR) was studied in normal post-menopausal breast epithelium. Normal breast epithelium from patients receiving hormone replacement therapy (HRT) at the time of surgery containing either oestrogen alone (E2) or oestrogen and progesterone combined activities (E2 + P) was also studied, as HRT has been linked to an increased breast cancer risk. Samples of breast tissue, containing normal epithelium, from 185 patients undergoing surgery for benign or malignant disease were immunocytochemically stained for PR and Ki67. The percentage of labelled cells was expressed as the labelling index (LI). The median Ki67 LI in normal post-menopausal breast epithelium was 0.19 and median PR LI was 4.75, and both were unaffected by patient age, duration of menopause or if the tissue sample originated from a breast with benign or malignant disease. Proliferation did not alter significantly in patients taking HRT (P = 0.61); however, PR expression was up-regulated in both E2 and E2 + P users (P = 0.01). The dose and duration of HRT had no effect on either parameter. A possible attenuation of sensitivity to oestradiol-induced proliferation but not to PR expression occurs in the post-menopausal breast.

Full text

PDF
945

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T. J., Ferguson D. J., Raab G. M. Cell turnover in the "resting" human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer. 1982 Sep;46(3):376–382. doi: 10.1038/bjc.1982.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergkvist L., Adami H. O., Persson I., Hoover R., Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989 Aug 3;321(5):293–297. doi: 10.1056/NEJM198908033210505. [DOI] [PubMed] [Google Scholar]
  3. Bromley M., Rew D., Becciolini A., Balzi M., Chadwick C., Hewitt D., Li Y. Q., Potten C. S. A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa. Eur J Histochem. 1996;40(2):89–100. [PubMed] [Google Scholar]
  4. Chang K. J., Lee T. T., Linares-Cruz G., Fournier S., de Ligniéres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995 Apr;63(4):785–791. [PubMed] [Google Scholar]
  5. Clarke R. B., Howell A., Anderson E. Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res Treat. 1997 Sep;45(2):121–133. doi: 10.1023/a:1005805831460. [DOI] [PubMed] [Google Scholar]
  6. Clarke R. B., Laidlaw I. J., Jones L. J., Howell A., Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer. 1993 Mar;67(3):606–611. doi: 10.1038/bjc.1993.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cline J. M., Soderqvist G., von Schoultz E., Skoog L., von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):93–100. doi: 10.1016/s0002-9378(96)70379-4. [DOI] [PubMed] [Google Scholar]
  8. Greendale G. A., Judd H. L. The menopause: health implications and clinical management. J Am Geriatr Soc. 1993 Apr;41(4):426–436. doi: 10.1111/j.1532-5415.1993.tb06953.x. [DOI] [PubMed] [Google Scholar]
  9. Harding C., Knox W. F., Faragher E. B., Baildam A., Bundred N. J. Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. BMJ. 1996 Jun 29;312(7047):1646–1647. doi: 10.1136/bmj.312.7047.1646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Horwitz K. B., McGuire W. L. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem. 1978 Apr 10;253(7):2223–2228. [PubMed] [Google Scholar]
  11. Jacquemier J. D., Hassoun J., Torrente M., Martin P. M. Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages--immunohistochemical study of 107 cases. Breast Cancer Res Treat. 1990 Feb;15(2):109–117. doi: 10.1007/BF01810783. [DOI] [PubMed] [Google Scholar]
  12. Jacquemier J. D., Rolland P. H., Vague D., Lieutaud R., Spitalier J. M., Martin P. M. Relationships between steroid receptor and epithelial cell proliferation in benign fibrocystic disease of the breast. Cancer. 1982 Jun 15;49(12):2534–2536. doi: 10.1002/1097-0142(19820615)49:12<2534::aid-cncr2820491221>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  13. Key T. J., Pike M. C. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988 Jan;24(1):29–43. doi: 10.1016/0277-5379(88)90173-3. [DOI] [PubMed] [Google Scholar]
  14. Laidlaw I. J., Clarke R. B., Howell A., Owen A. W., Potten C. S., Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology. 1995 Jan;136(1):164–171. doi: 10.1210/endo.136.1.7828527. [DOI] [PubMed] [Google Scholar]
  15. Lind T., Cameron E. C., Hunter W. M., Leon C., Moran P. F., Oxley A., Gerrard J., Lind U. C. A prospective, controlled trial of six forms of hormone replacement therapy given to postmenopausal women. Br J Obstet Gynaecol. 1979;86 (Suppl 3):1–29. doi: 10.1111/j.1471-0528.1979.tb16232.x. [DOI] [PubMed] [Google Scholar]
  16. McDivitt R. W., Stevens J. A., Lee N. C., Wingo P. A., Rubin G. L., Gersell D. Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group. Cancer. 1992 Mar 15;69(6):1408–1414. doi: 10.1002/1097-0142(19920315)69:6<1408::aid-cncr2820690617>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  17. McKinlay S. M., Brambilla D. J., Posner J. G. The normal menopause transition. Maturitas. 1992 Jan;14(2):103–115. doi: 10.1016/0378-5122(92)90003-m. [DOI] [PubMed] [Google Scholar]
  18. Meyer J. S. Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones. Hum Pathol. 1977 Jan;8(1):67–81. doi: 10.1016/s0046-8177(77)80066-x. [DOI] [PubMed] [Google Scholar]
  19. Meyer J. S., Connor R. E. Cell proliferation in fibrocystic disease and postmenopause breast ducts measured by thymidine labeling. Cancer. 1982 Aug 15;50(4):746–751. doi: 10.1002/1097-0142(19820815)50:4<746::aid-cncr2820500420>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  20. Moorhead T., Hannaford P., Warskyj M. Prevalence and characteristics associated with use of hormone replacement therapy in Britain. Br J Obstet Gynaecol. 1997 Mar;104(3):290–297. doi: 10.1111/j.1471-0528.1997.tb11456.x. [DOI] [PubMed] [Google Scholar]
  21. Pike M. C., Spicer D. V., Dahmoush L., Press M. F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15(1):17–35. doi: 10.1093/oxfordjournals.epirev.a036102. [DOI] [PubMed] [Google Scholar]
  22. Preston-Martin S., Pike M. C., Ross R. K., Jones P. A., Henderson B. E. Increased cell division as a cause of human cancer. Cancer Res. 1990 Dec 1;50(23):7415–7421. [PubMed] [Google Scholar]
  23. Soules M. R., Bremner W. J. The menopause and climacteric: endocrinologic basis and associated symptomatology. J Am Geriatr Soc. 1982 Sep;30(9):547–561. doi: 10.1111/j.1532-5415.1982.tb05661.x. [DOI] [PubMed] [Google Scholar]
  24. Sullivan J. M., Fowlkes L. P. Estrogens, menopause, and coronary artery disease. Cardiol Clin. 1996 Feb;14(1):105–116. doi: 10.1016/s0733-8651(05)70264-2. [DOI] [PubMed] [Google Scholar]
  25. Trichopoulos D., MacMahon B., Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 1972 Mar;48(3):605–613. [PubMed] [Google Scholar]
  26. Walker K. J., Price-Thomas J. M., Candlish W., Nicholson R. I. Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer. 1991 Oct;64(4):764–768. doi: 10.1038/bjc.1991.395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wellings S. R., Jensen H. M., Marcum R. G. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975 Aug;55(2):231–273. [PubMed] [Google Scholar]
  28. Whitehead M. I., Townsend P. T., Pryse-Davies J., Ryder T. A., King R. J. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med. 1981 Dec 31;305(27):1599–1605. doi: 10.1056/NEJM198112313052701. [DOI] [PubMed] [Google Scholar]
  29. Williams G., Anderson E., Howell A., Watson R., Coyne J., Roberts S. A., Potten C. S. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer. 1991 May 10;48(2):206–210. doi: 10.1002/ijc.2910480209. [DOI] [PubMed] [Google Scholar]
  30. Yates R. A., Dowsett M., Fisher G. V., Selen A., Wyld P. J. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer. 1996 Feb;73(4):543–548. doi: 10.1038/bjc.1996.94. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES